National Phase of: PCT/US00/04798

Attorney Docket No. 1059.00051

IN THE SPECIFICATION:

Page 40, Lines 5-16:

At first, the cDNA fragment, without adaptors encoding plasminogen kringles 1 to 5, was amplifies by a sense primer and a complementary primer: 5'CTCTCAGAGTGCAAGACTGGGAATGGAAAGAAC (Seq. ID. No. 1) (Leu100-Asn110), and 5'-GGCCGCACACTGAGGGACATCACAGTAGTC (Seq. ID. No. 2) (Ala562-Asp533 according to the amino acid sequence of human plasminogen) (Folkman, 1996). A cDNA fragment encoding collagen a1(XVIII) C-terminus was amplified by a set of primers: 5'CACAGCCACCGCGACTTCCAGCCGGTGCTC (Seq. ID. No. 3) (His1154-Leu1163) for the sense 5'-end of the peptide, and 5'-CTACTTGGAGGCAGTCATGAAGCTGTTCTCAAT (Seq. ID. No. 4) (Lys1336-Ile1327) for the complementary 3'-end (Folkman, 1996). Amplification of cDNA fragments performed by using a proof-reading thermostable Pfu DNA polymerase (Stratagene, La Jolla, CA).

Page 40, Lines 24-31 and Page 41, Lines 41, Lines 1-9:

Addition of adaptor to the amplified cDNA fragments was performed by PCR using adaptor anchored primers. Primers for cloning of the human plasminogen kringle 5 were 5'-GGAATTCCATATGGAAGAAGACTGTATGTTTGGG (Seq. ID. No. 5) (G-[EcoRI]-[NdeI]-[Glu478-Gyl486]), and 5'GGAATTCCATATGGGCCGCACACTGAGGGACATC (Seq. ID. No. 6) (G-[EcoRI]-[NdeI]-[Ala562-Asp556]). Collagen a1(XVIII) C-terminus with adaptors were amplified using primers 5'- GGAATTCCATATGCACAGCCACCGCGACTTCCAG (Seq. ID. No. 7) (G-[EcoRI]-[NdeI]-[His1154-Ile1160]), and 5'-CCGGGATCCCTACTTGGAGGCAGTCATGAAGCT (Seq. ID. No. 8) (CCG-[BamHI]-[STOP]-[Lys1336-Ser1330). PCR reaction solution (100 µI) contains 50 mM Tris (pH 8.8), 2 mM MgCI, 10 mM KCI, 10 µI of the above resulted PCR reaction mixture containing the cDNA fragments, 250 ng of each primer and 7.5 units of Pfu DNA

National Phase of: PCT/US00/04798 Attorney Docket No. 1059.00051

polmerase. Ten reaction PCR cycles consits of 45 sec at 94°C for denaturing, 45 sec at 97°C for annealing and 2 mins. At 68°C for DNA synthesis.

Page 53, Lines 4-17:

The tPA kringle 2 carrying mutation of His244 \rightarrow Tyr, is fused to collagen α 1 (XVIII) C-terminus. A 558 bp DNA fragment encoding 183 amino acid residues of human collagen α 1 (XVIII) C-terminus with adaptors that are amplified using primers 5'- GGAATTCCATATGCACAGCCACCGCGACTTCCAG (Seq. ID. No. 9) (G-[EcoRI]-

[Ndel]-[His1154→Gln1160]), and 5'-

CCGGGATCCCTACTTGGAGGCAGTCATGAAGCT (Seq. ID. No. 10) (CCG-[BamHI]-[STOP]-[Lys1336—Ser1330). A 287 bp cDNA fragment encoding 87 residues of tPA kringle 2 mutant H are amplified by primers 5'-GGAATTCCATAACAGTGACTGCTACTTTGGG (Seq. ID. No. 11) (G-[EcoRI]-[Ndel]-[Asn177—Gly183]), and 5'-GGAATTCCATATGGGTGGAGCAGGAGGGCACATC

Page 80, Lines 26-31 and Page 81, Lines 1-6:

(Sea. ID. No. 12) (G-[EcoRI]-[Ndel]-[Thr263→Asp257]).

59°C for annealing and 3 miniutes at 68°C for DNA synthesis. Kringle 1 was amplified by a 5'-end primer of GGAATTC-[Ndel]-

ATAGATACCAGGGCCACGTGCTACG (Seq. ID. No. 13), and a 3'-end primer of CCG-[BamHI]-TTAGTTTCCCTCAGAGCAGGCAGG (Seq. ID. No. 14). Kringle 2 was amplified by a set of primers: GGAATTC-[Ndel]-

AACAGTGACTGCTACTTTGGG (Seq. ID. No. 15) for 5'-end and CCG-[BamHI]-TTAGGTGGAGCAGGAGGCACATC (Seq. ID No. 16) for 3'-end. A DNA fragment containing both of kringles was also amplified by a 5'-end primer of GGAATTC-[NdeI]-ATAGATACCAGGGCCACGTGCTACG (Seq. ID. No. 17), and a 3'-end primer CCG-[BamHI]-TTAGGTGGAGCAGGAGGGCACATC (Seq. ID. No. 18). Where GGAATTC-[NdeI]- and CCG[BamHI]- are adaptors containing NdeI and BamHI recognition sites.

National Phase of: PCT/US00/04798 Attorney Docket No. 1059.00051

Page 82, Lines 6-31:

Oligonucleotide primers designed for mutagenesis PCR are listed. Where, the mutation sites are underlined. Residue numbers are according to the amino acid sequence of tPA.

S mutant (Ser186 - Lys mutation):

SKf-1, sense, 5 'GCTACTTTGGGAATGGG<u>AAA</u>GCCTACCGTGGC-3' (Seq. ID. No. 19)

SKr-2, anti-sense, 5'-GCCACGGTAGGC<u>TTT</u>CCCATTCCCAAAGTAGC-3' (Seq. ID. No. 20)

Y mutant (Tvr214 - Phe mutation):

YFf-3, sense, 5'-CCTGATAGGCAAGGTT<u>TTC</u>ACAGCACAGAACCCC-3' (Seq. ID. No. 21)

Yfr-4, anti-sense, 5'-GGGGTTCTGTGCTGT<u>GAA</u>AACCTTGCCTATCAGG-3' (Seq. ID. No. 22)

N mutant (Asn218 - Thr mutation):

NTf-5, sense, 5'-GTTTACACAGCACAG<u>ACC</u>CCCAGTGCCCAGGC-3' (Seq. ID. No. 23)

NTr-6, anti-sense, 5'-GCCTGGGCACTGGG<u>GGT</u>CTGTGCTGTGTAAAC-3' (Seq. ID. No. 24)

G mutant (Gly225 - Glu mutation):

GEf-7, sense, 5'-GTGCCCAGGCACTG<u>GAA</u>CTGGGCAAACATAAT-3' (Seq. ID. No. 25)

GEr-8, anti-sense, 5'-ATTATGTTTGCCCAG<u>TTC</u>CAGTGCCTGGGCAC-3' (Seq. ID. No. 26)

K mutant (Lys240 - Gly-Gly mutation):

KGGf-9, sense, 5'-CCTGATGGGGATGCC<u>GGTGGC</u>CCCCTGGTGCCACG-3' (Seq. ID. No. 27)

KGGf-10, anti-sense, 5'-CGTGGCACCAGGG<u>GCCACC</u>GGCATCCCCATCAGG-3' (Seq. ID. No. 28)

H mutant (His244 - Tyr mutation):

National Phase of: PCT/US00/04798 Attorney Docket No. 1059.00051

HYf-11, sense, 5'-GCCAAGCCCTGGTGC<u>TAT</u>GTGCTGAAGAACCGC-3' (Seq. ID. No. 29)

HYr-12, anti-sense, 5'-GCGGTTCTTCAGCAC<u>ATA</u>GCACCAGGGCTTGGC-3' (Seq. ID. No. 30)

W mutant (Trp253-Glu254 - Tyr-Asp mutation):

WEYDf-13, sense, 5'-CCGCAGGCTGACG<u>TATGAT</u>TACTGTGATGTGCCC (Seq. ID. No. 31)

WEYDr-14, anti-sense, 5'-GGGCACATCACAGTA<u>ATCATA</u>CGTCAGCCTGCGG (Seq. ID. No. 32)

Page 102, Lines 23-31 and Page 103, Lines 1-25:

- Change Y18I to M. Oligonucleotide primers will be 5'-CAGTGACTGCATGTTTGGGAATGGG-3' (Seq. ID. No. 33) and 5'-CCCATTCCCAAACATGCAGTCACTA-3' (Seq. ID. No. 34).
- Change Tl91 to K. Oligonucleotide primers will be 5'-CCTACCGTGGCAAACACAGCCTCACC-3' (Seq. ID. No. 35) and 5'-GGTGAGGCTGTGTTTGCCACGGTAGG-3' (Seq. ID. No. 36).
- Change S193 to A. Oligonucleotide primers will be 5'-CCGTGGCACGCCCTCACCGAG-3' (Seq. ID. No. 37) and 5'-CTCGGTGAGGGCGTGCGTGCCACGG-3' (Seq. ID. No. 38).
- Change S206 to A. Oligonucleotide primers will be 5'-CCCGTGGAATGCCATGATCCTGATAG-3' (Seq. ID. No. 39) and 5'-CTATCAGGATCATGGCATTCCACGGG-3' (Seq. ID. No. 40).
- Change D236 to P. Oligonucleotide primers will be 5'-GCCGGAATCCTCCGGGGGATGCC-3' (Seq. ID. No. 41) and 5'-GGCATCCCCGGAGGATTCCGGC -3' (Seq. ID. No. 42).
- Change K240 to G. Oligonucleotide primers will be 5'-GATGGGGATGCCGGGCCCTGGTGCC-3' (Seq. ID. No. 43)

Serial No.: 09/914,277 National Phase of: PCT/US00/04798 Attorney Docket No. 1059.00051

and 5'-GGCACCAGGGCCCGGCATCCCCATC- 3' (Seq. ID. No. 44).

- Change W253 to Y. Oligonucleotide primers will be 5'-CGCAGGCTGACGTACGAGTACTGTG-3' (Seq. ID. No. 45) and 5'-CACAGTACTCGTACGTCAGCCTGCG-3' (Seq. ID. No. 46).
- Change E254 to D. Oligonucleotide primers will be
 5'-GGCTGACGTGGGACTACTGTGATGTG-3' (Seq. ID. No. 47) and
 5'-CACATCACAGTAGTCCCACGTCAGCC-3' (Seq. ID. No. 48).
- Change S262 to A. Oligonucleotide primers will be
 5'-GTGCCCTCCTGCGCCACCTAAGGATCC-3' (Seq. ID. No. 49) and
 5'-GGATCCTTAGGTGGCGCAGGAGGGCAC-3' (Seq. ID. No. 50).

Page 104, Lines 5-31 and Page 105, Lines 1-4:

- Mutate F182 to H. Oligonucleotide primers will be 5'-GACTGCTACCACGGGAATGGGTCAG-3' (Seq. ID. No. 51) and 5'-CTGACCCATTCCCGTGGTAGCAGTC-3' (Seq. ID. No. 52).
- Mutate A223 to N. Oligonucleotide primers will be 5'-CCCAGTGCCCAGAACCTGGGCCTGG-3' (Seq. ID. No. 53) and 5'-CCAGGCCCAGGTTCTGGGCACTGGG-3' (Seq. ID. No. 54).
- Mutate W242 to T. Oligonucleotide primers will be 5'-GATGCCAAGCCCACCTGCCACGTGCTG-3' (Seq. ID. No. 55) and 5'-CAGCACGTGGCAGGTGGGCTTGGCATC-3' (Seq. ID. No. 56).
- Mutate R249 to P. Oligonucleotide primers will be 5'-GTGCTGAAGAACCCCAGGCTGACGTG-3' (Seq. ID. No. 57) and 5'-CACGTCAGCCTGGGGTTCTTCAGCAC -3' (Seq. ID. No. 58).
- Mutate L251 to V. Oligonucleotide primers will be

Serial No.: 09/914,277 National Phase of: PCT/US00/04798 Attorney Docket No. 1059,00051

- 5'-GAACCGCAGGGTGACGTGGGAGTAC-3' (Seq. ID. No. 59) and 5'-GTACTCCCACGTCACCCTGCGGTTC-3' (Seq. ID. No. 60).
- Mutate D257 to N. Oligonucleotide primers will be
 5'-GTGGGAGTACTGTAACGTGCCCTCC-3' (Seq. ID. No. 61) and
 5'-GGAGGGCACGTTACAGTACTCCCAC-3' (Seq. ID. No. 62).
- Mutate V258 to L. Oligonucleotide primers will be 5'-GAGTACTGTGATCTGCCCTCCTGCTC-3'(Seq. ID. No. 63) and 5'-GAGCAGGAGGGCAGATCACAGTACTC-3' (Seq. ID. No. 64).
- Mutate P259 to K. Oligonucleotide primers will be
 5'-GTACTGTGATGTGAAGTCCTGCTCC-3' (Seq. ID. No. 65) and
 5'-GGAGCAGGACTTCACATCACAGTAC-3' (Seq. ID. No. 66).

Page 108: Lines 16-19:

Amino Acid presentation of tPA kringle 2. $(K2_{IPA})$ NSDCYFGNGSAYRGTHSLTESGASCLPMSHILIGKYYTAQNPSAQALGLGKHYYCRNPDGDAKPWCHYLKNRRLTWEYCDVPSCST (Seq. ID. No. 67)

Amino Acid presentation of tPA kringle 2.(K2,)

NSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKYYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCST (Seq. ID. No. 67)

Page 109; Lines 1-23:

NSDCYFGHGSAYRGTHSLTESGASCLPWNSH

ILEGKYYTAQNPSAQALGLGKHNYCRNP9GDAKPWCHYLKNRRLTWEYCDVPSCST (Seq. ID. No. 67)

Enzymatic fragmentation of $K2_{\text{LPA}}$ at its two glutamyl bonds are performed with the GluV8 form of glutamyl endopeptidase 1, at optimal conditions to yield three peptides. The reaction is stopped with Cbz-Leu-Leu-Glu-CH₂Cl and the fragments separated by hplc.

Glutamyl endopeptidase -!Staph. aureus V-8 Protease); cleavage after E(Glu)

NSDCYFGNGSAYRGTHSLTE
SGASCLPWNSMILIGKYYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWE
YCDVPSCST (Seq. ID. No. 67)

Prolyl oligopeptidase is used to cleave specifically the Pro-Xaa bonds in $K2_{\text{tPA}}$. Since this protease cleaves only small polypeptides, it is used in combination with CNBr and GluV8 to generate smaller fragments. However, if $K2_{\text{tPA}}$ is susceptible to this post-proline cleaving enzyme a 27 -residue, three 16-18 residue and two small (4-6 residue) peptide fragments spanning the $K2_{\text{tPA}}$ domain can be obtained.

Post-Proline cleaving enzyme; cleavage after P (Pro)

NSÖCYFGNGSAYRGTHSLTESGASCLP

WNSMILIGKVYTAQNP

SAQALGLGKHNYCRNP DGDAKP

WCHVLKNRRLTWEYCDVP

SCST (Seq. ID. No. 67)

Serial No.: 09/914,277 National Phase of: PCT/US00/04798 Attomey Docket No. 1059.00051

Please replace the Sequence Listing that follows the Abstract of this application and replace it with the attached Sequence Listing.